Multiple myeloma other diagnostic studies: Difference between revisions

Jump to navigation Jump to search
Shyam Patel (talk | contribs)
Shyam Patel (talk | contribs)
No edit summary
Line 9: Line 9:
*Bone marrow biopsy is usually performed in most patients with a suspected diagnosis of multiple myeloma or other hematologic malignancy. It is usually done as part of the initial diagnostic workup.  
*Bone marrow biopsy is usually performed in most patients with a suspected diagnosis of multiple myeloma or other hematologic malignancy. It is usually done as part of the initial diagnostic workup.  
*Bone marrow biopsy is usually performed to estimate the percentage of bone marrow occupied by plasma cells.<ref name="canada">Multiple myeloma. Canadian Cancer Society(2015) http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/diagnosis/?region=mb#blood_chem Accessed on September, 20th 2015</ref>
*Bone marrow biopsy is usually performed to estimate the percentage of bone marrow occupied by plasma cells.<ref name="canada">Multiple myeloma. Canadian Cancer Society(2015) http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/diagnosis/?region=mb#blood_chem Accessed on September, 20th 2015</ref>
*Bone marrow biopsy consists of both a liquid aspirate and a solid core biology. Immunophenotyping (flow cytometry) is usually done on the bone marrow aspirate to assess for abnormal cells. Of note, plasma cells are particularly susceptible to mechanical damage by immunophenotyping, so this is not the best way to assess for plasma cell burden in the bone marrow. A better method is to assess the core biopsy for plasma cell content. Cytogenetics (chromosome analysis) can be performed on the the core biopsy. Molecular studies are usually performed  
*Bone marrow biopsy consists of both a liquid aspirate and a solid core biology. Immunophenotyping (flow cytometry) is usually done on the bone marrow aspirate to assess for abnormal cells. Of note, plasma cells are particularly susceptible to mechanical damage by immunophenotyping, so this is not the best way to assess for plasma cell burden in the bone marrow. A better method is to assess the core biopsy for plasma cell content. Cytogenetics (chromosome analysis) can be performed on the the core biopsy. Molecular studies are usually performed on the aspirate
*The percentage of plasma cells is used of one of the key diagnostic criteria of multiple myeloma.<ref name="canada">Multiple myeloma. Canadian Cancer Society(2015) http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/diagnosis/?region=mb#blood_chem Accessed on September, 20th 2015</ref> A diagnosis of multiple myeloma requires greater than 10% clonal plasma cells in the bone marrow.
*The percentage of plasma cells is used of one of the key diagnostic criteria of multiple myeloma.<ref name="canada">Multiple myeloma. Canadian Cancer Society(2015) http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/diagnosis/?region=mb#blood_chem Accessed on September, 20th 2015</ref> A diagnosis of multiple myeloma requires greater than 10% clonal plasma cells in the bone marrow.


Line 15: Line 15:


'''[[Karyotyping]]'''
'''[[Karyotyping]]'''
:*Detects any [[chromosomal]] [[mutations]] occurring in multiple myeloma such as chromosome 13 deletion.<ref name="canada">Multiple myeloma. Canadian Cancer Society(2015) http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/diagnosis/?region=mb#blood_chem Accessed on September, 20th 2015</ref><ref name="wiki">Multiple myeloma. Wikipedia (2015)https://en.wikipedia.org/wiki/Multiple_myeloma#Pathophysiology Accessed on September 2015</ref>
:*Detects any [[chromosomal]] [[abnormalities n multiple myeloma such as chromosome 13 deletion.<ref name="canada">Multiple myeloma. Canadian Cancer Society(2015) http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/diagnosis/?region=mb#blood_chem Accessed on September, 20th 2015</ref><ref name="wiki">Multiple myeloma. Wikipedia (2015)https://en.wikipedia.org/wiki/Multiple_myeloma#Pathophysiology Accessed on September 2015</ref>


'''[[Fluorescent in situ hybridization]] (FISH)'''
'''[[Fluorescent in situ hybridization]] (FISH)'''

Revision as of 05:48, 12 August 2018

Multiple myeloma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple Myeloma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Multiple myeloma other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple myeloma other diagnostic studies

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple myeloma other diagnostic studies

CDC on Multiple myeloma other diagnostic studies

Multiple myeloma other diagnostic studies in the news

Blogs on Multiple myeloma other diagnostic studies

Directions to Hospitals Treating Multiple myeloma

Risk calculators and risk factors for Multiple myeloma other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]

Overview

Cytology and/or histology, cytogenetic investigation (chromosome analysis and FISH) may be helpful in the diagnosis of multiple myeloma to detect unfavorable cytogenetic aberrations.[1] PMID:27476706 On bone marrow biopsy, multiple myeloma is characterized by an increase in percentage of abnormal plasma cells.[1] On genetic testing, multiple myeloma is characterized by chromosome 13 deletion and chromosome 14 translocation.[1][2]

Bone Marrow Biopsy

  • Bone marrow biopsy is usually performed in most patients with a suspected diagnosis of multiple myeloma or other hematologic malignancy. It is usually done as part of the initial diagnostic workup.
  • Bone marrow biopsy is usually performed to estimate the percentage of bone marrow occupied by plasma cells.[1]
  • Bone marrow biopsy consists of both a liquid aspirate and a solid core biology. Immunophenotyping (flow cytometry) is usually done on the bone marrow aspirate to assess for abnormal cells. Of note, plasma cells are particularly susceptible to mechanical damage by immunophenotyping, so this is not the best way to assess for plasma cell burden in the bone marrow. A better method is to assess the core biopsy for plasma cell content. Cytogenetics (chromosome analysis) can be performed on the the core biopsy. Molecular studies are usually performed on the aspirate
  • The percentage of plasma cells is used of one of the key diagnostic criteria of multiple myeloma.[1] A diagnosis of multiple myeloma requires greater than 10% clonal plasma cells in the bone marrow.

Cytogenetic Tests

Karyotyping

  • Detects any chromosomal [[abnormalities n multiple myeloma such as chromosome 13 deletion.[1][2]

Fluorescent in situ hybridization (FISH)

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Multiple myeloma. Canadian Cancer Society(2015) http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/diagnosis/?region=mb#blood_chem Accessed on September, 20th 2015
  2. 2.0 2.1 2.2 Multiple myeloma. Wikipedia (2015)https://en.wikipedia.org/wiki/Multiple_myeloma#Pathophysiology Accessed on September 2015


Template:WikiDoc Sources